Cerbios’ recombinant urokinase is obtained by rDNA technology from a CHO cell line through a proprietary process.
Cerbios’ rUK is obtained by “state of the art” rDNA technology from a CHO cell line and is therefore glycosilated. The product will start clinical trials during 2017 and licensing opportunities are expected for the USA and Canada
Extractive urokinase is an enzyme used in human medicine for clot lysis in various indications (such as peripheral arterial occlusion, deep venous thrombosis, stroke, catheter clearance, myocardial infarction). Its biological function consists in the activation of plasminogen to plasmin, allowing for the restoration of patency of blood vessels obstructed by thrombus formation or fibrin sleeves.